All In MedTech

Device Trial Radar · NCT07757113

Comparative Study of Embolic Agents in Patients With Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Mar 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Sanford HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
phenox Inc.
First posted
Aug 11, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Single site, prospective, comparative effectiveness pilot trial comparing efficacy and safety outcomes of three embolic materials (particles, liquid embolics, and Wallaby Phenox coils) in MMA embolication for cSDH.

Conditions

  • Chronic Subdural Hematoma
  • Stroke
  • Middle Meningeal Artery Embolization

Interventions

  • Particles (polyvinyl alcohol or similar microspheres)Device

    Participants will be sequentially enrolled into one of three clinically accepted MMAE treatment strategies (interventions) to compare radiographic and clinical outcomes.

  • Liquid Embolics (Onyx, n-BCA, or equivalent)Device

    Participants will be sequentially enrolled into one of three clinically accepted MMAE treatment strategies (interventions) to compare radiographic and clinical outcomes.

  • Phenox Coils (Avenir UNO Helical Coil)Device

    Participants will be sequentially enrolled into one of three clinically accepted MMAE treatment strategies (interventions) to compare radiographic and clinical outcomes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hematoma sizeTime frame: Baseline, 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanford USD Medical Center

    Sioux Falls, South Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.